Skip to main content

Advertisement

SpringerLink
Log in

Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Numerous clinical studies have shown that anti-EGFR therapies are effective only in a subset of patients with colorectal cancer. Even though mutations in the KRAS gene have been confirmed as negative predictors of the response to EGFR-targeted therapies, not all KRAS wild-type (wt-KRAS) patients will respond to treatment. Recent studies have demonstrated that additionally wild-type BRAF (wt-BRAF) genotype is required for response to panitumumab or cetuximab, suggesting that BRAF genotype criteria should be used together with KRAS genotype for selecting the patients who are about to benefit from the anti-EGFR therapy. In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene. Among the tested patients, 53.8% of patients had wt-KRAS genotype and 46.2% were KRAS mutants. Around five percent (5.1%) of the tested patients bore the V600E mutation in BRAF gene. All the patients showing to have the V600E mutation in BRAF were wt-KRAS. The concordance of KRAS and BRAF mutational status between primary and metastatic tumor tissue samples was 100%. We have shown that the proportions of mutated and non-mutated KRAS in Slovene patients, as well as the proportion of V600E mutations in BRAF is similar to genotyping results reported by other authors. The tested seven KRAS mutations on codons 12 and 13 were mutually exclusive with the V600E mutation in the BRAF gene. Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non-responsive patients for the anti-EGFR treatment is 51.3%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Bioll Cell. 2001;93:53–62.

    Article  CAS  Google Scholar 

  2. Harari PM, Allen GW, Bonner JA. Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057–65.

    Article  PubMed  CAS  Google Scholar 

  3. Hemming AW, et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol. 1992;51:147–52.

    Article  PubMed  CAS  Google Scholar 

  4. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davies NJ. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. J Surg Oncol. 1992;1:97–105.

    Article  CAS  Google Scholar 

  5. Mayer A, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454–60.

    Article  PubMed  CAS  Google Scholar 

  6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.

    Article  PubMed  CAS  Google Scholar 

  7. Spano JP, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16:102–8.

    Article  PubMed  Google Scholar 

  8. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007;13:4606s–12s.

    Article  CAS  Google Scholar 

  9. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62:53–61.

    Article  PubMed  Google Scholar 

  10. Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Cancer J Clin Oncol. 2008;26:1626–34.

    CAS  Google Scholar 

  11. Kimura H, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007;98:1275–80.

    Article  PubMed  CAS  Google Scholar 

  12. Lievre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with Cetuximab. J Clin Oncol. 2008;26(3):374–9.

    Article  PubMed  CAS  Google Scholar 

  13. De Roock W, et al. KRAS mutation status and early radiological response predict survival in colorectal cancer treated with Cetuximab. Ann Oncol. 2008;19:508–15.

    Article  PubMed  Google Scholar 

  14. Zenker M, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007;44:131–5.

    Article  PubMed  CAS  Google Scholar 

  15. Van Krieken JHJM, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453(5):417–31.

    Article  PubMed  Google Scholar 

  16. Linardou H, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–72.

    Article  PubMed  CAS  Google Scholar 

  17. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2001;417:949–54.

    Article  Google Scholar 

  18. Sala E, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008;6(5):751–9.

    Article  PubMed  CAS  Google Scholar 

  19. Kim IJ, et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet. 2003;114:118–20.

    Article  PubMed  CAS  Google Scholar 

  20. Kumar R, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003;9:3362–8.

    PubMed  CAS  Google Scholar 

  21. Di Nicolantino F, et al. Wild Type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705–12.

    Article  Google Scholar 

  22. Bardelli A, Sienna S. Molecular mechanysms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254–61.

    Article  PubMed  CAS  Google Scholar 

  23. Laurent-Puig P, et al. Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924–31.

    Article  PubMed  CAS  Google Scholar 

  24. Benlloch S, et al. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn. 2006;8(5):540–3.

    Article  PubMed  CAS  Google Scholar 

  25. Bos JL, et al. Prevalence of ras mutations in human colorectal cancers. Nature. 1987;327:293–7.

    Article  PubMed  CAS  Google Scholar 

  26. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–6.

    Article  PubMed  CAS  Google Scholar 

  27. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–99.

    Article  PubMed  CAS  Google Scholar 

  28. Di Fiore F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166–9.

    Article  PubMed  CAS  Google Scholar 

  29. Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes’ C colorectal cancer. J Pathol. 2001;195:543–8.

    Article  PubMed  CAS  Google Scholar 

  30. Neuman J, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205(12):858–62.

    Article  Google Scholar 

  31. Yuen S, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62:6451–5.

    PubMed  CAS  Google Scholar 

  32. Roth AD, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2009;28(3):466–74.

    Article  PubMed  Google Scholar 

  33. Rajagopalan H, et al. Tumorigenesis: RAF/RAS oncogenes, mismatch-repair status. Nature. 2002;418:934.

    Article  PubMed  CAS  Google Scholar 

  34. Artale S, Sartore-Bianchi A, Veronese SM. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008;26(25):4217–9.

    Article  PubMed  Google Scholar 

  35. Santini D, Loupakis F, Vincenzi B. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practise. Oncologist. 2008;13:1270–5.

    Article  PubMed  CAS  Google Scholar 

  36. Velho S, et al. BRAF, KRAS, PIK3CA mutations in colorectal serrated polyps, cancer: primary or secondary genetic events in colorectal carcinogenesis. BMC Cancer. 2008;8:255.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Zaloška 2, 1000, Ljubljana, Slovenia

    Alenka Ličar, Petra Cerkovnik & Srdjan Novaković

Authors
  1. Alenka Ličar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petra Cerkovnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Srdjan Novaković
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srdjan Novaković.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ličar, A., Cerkovnik, P. & Novaković, S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 28, 1048–1053 (2011). https://doi.org/10.1007/s12032-010-9631-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9631-z

Keywords

Search

Navigation